SHENZHEN, China, Aug. 26 /PRNewswire-FirstCall/ - Hard to Treat Diseases (the "Company") (HTDS.PK) www.htdsmedical.com provides access to U.S. Patent and Trademark Office.("USPTO") documents relating to intellectual property ("IP") ownership rights of the Company.
HTDS management has duly notified the OTCBB company utilizing the IP rights of the Company and is providing its shareholders with certain other "Supplementary" filings made yesterday with Pink Sheets. The information can be accessed at http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds
The supplementary filings made on Pink Sheets by HTDS include the actual copies of the USPTO recording documents, the letter to the OTCBB Company utilizing HTDS rights and proof of FedEx delivery of the same.
These documents are self explanatory.
HTDS management is of the opinion that this information is material, and both issuers need to disclose its potential effect to its shareholders and investors. The OTCBB company is in default in their filings with the SEC. and has received an "e" on its symbol as a late filing issuer.
HTDS ownership rights for the five patents can be accessed at the following five USPTO websites:
HTDS management will continue to monitor the situation and intends to vigorously escalate its claim to protect its interests. The Company is not ruling out any available options at this point regarding the IP rights that may have a positive significant impact on the entire value of HTDS.
Further updates to follow.
Safe Harbor Statement:
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved